Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:ANPC NASDAQ:BTCY NASDAQ:MTVA NASDAQ:OPGN On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeANPCFresh2 Group$4.37$4.92$2.60▼$11.99$4.24M1.5526,396 shs35,704 shsBTCYBiotricity$0.70-3.5%$0.51$0.19▼$0.83$17.43M1.1937,452 shs5,918 shsMTVAMetaVia$1.27+82.5%$0.66$0.56▼$3.75$30.74M0.25396,837 shs38.62 million shsOPGNOpGen$0.00$2.58$0.00▼$0.00$1K-1.77490 shs152 shsA Guide To High-Short-Interest StocksMarketBeat's analysts have just released their top five short plays for September 2025. Learn which stocks have the most short interest and how to trade them. Enter your email address to see which companies made the list.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceANPCFresh2 Group0.00%0.00%0.00%0.00%0.00%BTCYBiotricity0.00%+5.10%+15.04%+42.59%+86.43%MTVAMetaVia0.00%+0.87%+8.73%-4.55%+69,589,900.00%OPGNOpGen0.00%0.00%0.00%-100.00%-100.00%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeANPCFresh2 Group$4.37$4.92$2.60▼$11.99$4.24M1.5526,396 shs35,704 shsBTCYBiotricity$0.70-3.5%$0.51$0.19▼$0.83$17.43M1.1937,452 shs5,918 shsMTVAMetaVia$1.27+82.5%$0.66$0.56▼$3.75$30.74M0.25396,837 shs38.62 million shsOPGNOpGen$0.00$2.58$0.00▼$0.00$1K-1.77490 shs152 shsA Guide To High-Short-Interest StocksMarketBeat's analysts have just released their top five short plays for September 2025. Learn which stocks have the most short interest and how to trade them. Enter your email address to see which companies made the list.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceANPCFresh2 Group0.00%0.00%0.00%0.00%0.00%BTCYBiotricity0.00%+5.10%+15.04%+42.59%+86.43%MTVAMetaVia0.00%+0.87%+8.73%-4.55%+69,589,900.00%OPGNOpGen0.00%0.00%0.00%-100.00%-100.00%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceANPCFresh2 Group 0.00N/AN/AN/ABTCYBiotricity 2.00HoldN/AN/AMTVAMetaVia 3.00Buy$7.50490.50% UpsideOPGNOpGen 0.00N/AN/AN/ACurrent Analyst Ratings BreakdownLatest ANPC, OPGN, BTCY, and MTVA Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails9/4/2025MTVAMetaViaHC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingInitiated CoverageBuy$12.00(Data available from 9/15/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookANPCFresh2 Group$1.75M2.42N/AN/A($1.41) per share-3.10BTCYBiotricity$12.06M1.45N/AN/A($1.30) per share-0.54MTVAMetaViaN/AN/AN/AN/A$0.92 per shareN/AOPGNOpGen$2.67M0.00N/AN/A($11.55) per share0.00Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateANPCFresh2 Group-$14.77MN/A0.00∞N/AN/AN/AN/AN/ABTCYBiotricity-$14.09M-$0.21N/A∞N/A-80.42%N/A-188.47%11/13/2025 (Estimated)MTVAMetaVia-$27.59MN/A0.00N/AN/AN/A-212.00%-107.21%11/6/2025 (Estimated)OPGNOpGen-$32.67MN/A0.00∞N/A-1,140.36%N/A-287.58%11/13/2025 (Estimated)Latest ANPC, OPGN, BTCY, and MTVA EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails8/7/2025Q2 2025MTVAMetaVia-$0.32-$0.26+$0.06-$0.26N/AN/ACompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthANPCFresh2 GroupN/AN/AN/AN/AN/ABTCYBiotricityN/AN/AN/AN/AN/AMTVAMetaViaN/AN/AN/AN/AN/AOPGNOpGenN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioANPCFresh2 GroupN/A0.320.32BTCYBiotricityN/A0.230.10MTVAMetaViaN/A2.082.08OPGNOpGenN/A5.455.45Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipANPCFresh2 Group45.84%BTCYBiotricity3.89%MTVAMetaVia1.37%OPGNOpGen2.68%Insider OwnershipCompanyInsider OwnershipANPCFresh2 Group26.22%BTCYBiotricity10.10%MTVAMetaVia0.80%OPGNOpGen43.80%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableANPCFresh2 Group86970,000715,000Not OptionableBTCYBiotricity4024.91 million22.08 millionOptionableMTVAMetaVia824.20 million24.00 millionN/AOPGNOpGen10010.07 million4.70 millionNot OptionableANPC, OPGN, BTCY, and MTVA HeadlinesRecent News About These CompaniesOpGen Delays Filing of Quarterly ReportAugust 14, 2025 | tipranks.comOpGen Forms Joint Venture with European BankMay 29, 2025 | tipranks.comOpGen Delays 10-Q Filing Amid Operational ChallengesMay 16, 2025 | tipranks.comOpGen Inc ziet aanzienlijke aankoop van aandelen door AEI Capital LtdDecember 11, 2024 | nl.investing.comOpGen Inc aandeelhouder AEI Capital Ltd verhoogt belang met aankoop van €1,9 biljoenDecember 10, 2024 | nl.investing.comOpGen Appoints New COO and Company SecretaryDecember 6, 2024 | tipranks.comOpGen (OTC:OPGN) Stock Quotes, Forecast and News SummaryOctober 5, 2024 | benzinga.comOPGN Stock Earnings: OpGen Reported Results for Q2 2024August 21, 2024 | investorplace.comOPGN Stock Earnings: OpGen Reported Results for Q1 2024July 8, 2024 | investorplace.comOPGN Stock Earnings: OpGen Meets Revenue for Q4 2023June 5, 2024 | investorplace.comOpgen Inc (NASDAQ:OPGN) stock Posted Gross Margin of 6.62 percent in Last Year: Is Justifiable?May 27, 2024 | bovnews.comBOpGen, Inc.: OpGen Receives Expected Nasdaq Notice Regarding Delayed Form 10-QMay 25, 2024 | finanznachrichten.deOpGen Receives Expected Nasdaq Notice Regarding Delayed Form 10-QMay 24, 2024 | globenewswire.comOpGen to Execute 1-for-10 Reverse Stock SplitMay 16, 2024 | 360dx.com3OpGen, Inc.: OpGen Announced 1-for-10 Reverse Stock SplitMay 16, 2024 | finanznachrichten.deOpGen Announced 1-for-10 Reverse Stock SplitMay 16, 2024 | globenewswire.comOpGen, Inc. (OPGN) stock price, news, quote & history – Yahoo FinanceMay 4, 2024 | uk.finance.yahoo.comOpGen, Inc.: OpGen Provides Update on Business Operations and Strategic OpportunitiesApril 30, 2024 | finanznachrichten.deOpGen Provides Update on Business Operations and Strategic OpportunitiesApril 29, 2024 | globenewswire.comOpGen CEO David Lazar buys additional shares worth $150kApril 27, 2024 | investing.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeANPC, OPGN, BTCY, and MTVA Company DescriptionsFresh2 Group NASDAQ:ANPCAnPac Bio-Medical Science Co., Ltd., a biotechnology company, researches, develops, markets, and sells multi-cancer screening and detection tests using cancer differentiation analysis technology and device to corporations and life insurance companies in the People's Republic of China. It also offers physical checkup package services. The company was incorporated in 2010 and is headquartered in Lishui, the People's Republic of China.Biotricity NASDAQ:BTCY$0.70 -0.03 (-3.50%) As of 01:15 PM EasternBiotricity, Inc., a medical technology company, provides biometric data monitoring solutions in the United States. The company focuses on delivery of remote monitoring solutions to medical, healthcare, and consumer markets, including diagnostic and post-diagnostic solutions for lifestyle and chronic illnesses. It offers Bioflux mobile cardiac telemetry solution, an integrated ECG device; and ECG analysis software that analyzes and synthesizes patient ECG monitoring data, as well as software components. The company is based in Redwood City, California.MetaVia NASDAQ:MTVA$1.27 +0.57 (+82.51%) As of 02:22 PM EasternMetaVia Inc. is a clinical-stage biotechnology company focused on transforming cardiometabolic diseases. MetaVia Inc., formerly known as NeuroBo Pharmaceuticals Inc., is based in CAMBRIDGE, Mass.OpGen NASDAQ:OPGN$0.0001 0.00 (0.00%) As of 10:04 AM EasternOpGen, Inc., a precision medicine company, engages in developing and commercializing molecular microbiology solutions in the United States and internationally. Its product portfolio includes Acuitas AMR Gene Panel, an in vitro diagnostic (IVD) test for the detection and identification of various bacterial nucleic acids and genetic determinants of antimicrobial resistance (AMR) from bacterial colonies isolated from any specimen, as well as Curetis CE-IVD-marked polymerase chain reaction-based SARS-CoV-2 test kits. The company's products also comprise ARES Technology Platform, including ARES reference database on antimicrobial resistance using next generation sequencing technology and artificial intelligence powered bioinformatics solutions for antibiotic response prediction; and Unyvero Platform, an automated sample-to-answer molecular diagnostics platform that integrates automated sample preparation, analysis, and identification of disease relevant pathogens and antibiotic resistance markers. It also utilizes molecular diagnostics and informatics to help combat infectious diseases. The company helps clinicians with information about life threatening infections to enhance patient outcomes, and to decrease the spread of infections caused by multidrug-resistant microorganisms. OpGen, Inc. has a collaboration with the New York State Department of Health and ILÚM Health Solutions, LLC to develop a research program to detect, track, and manage antimicrobial-resistant infections at healthcare institutions. The company was incorporated in 2001 and is headquartered in Rockville, Maryland. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Palantir’s Commercial Growth Story Is Just Getting Started The Applied Digital Breakout Is Only the Beginning $100 Million Buyback in Upwork Stock Follows a Strong Quarter Royal Caribbean's 33% Dividend Hike Signals Deeper Growth MarketBeat Week in Review – 09/08 - 09/12 Adobe’s Rebound Has Room to Run: 25% Upside by Year-End Wall Street Eyes +30% Upside in Synopsys After Huge Earnings Fall Meta's $600B U.S. Investment: Bearish or Bullish for Shares? Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
